Collaborations and publications are strong proofs of the relevance of our research.
H-Factor: Dr. Laurent Meijer (73)

Cystic Fibrosis (CF)

  1. Marteyn, B.S., Burgel, P.R., Meijer, L. and Witko-Sarsat, V., 2017. Harnessing neutrophil survival mechanisms during chronic infection by Pseudomonas aeruginosa: novel therapeutic targets to dampen inflammation in cystic fibrosis. Front. Cell. Infect. Microbiol. 7, 243.
  2. Meijer, L., Nelson, D., Riazanski, V., Gabdoulkhakova, A.G., Hery-Arnaud, G., Leberre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., Gueganton, L., Dorothée, G., Prochazkova, M., Hall, B., Kulkarni, A.B., Gray, R.D., Rossi, A.G., Witko-Sarsat, V., Norez, C., Becq, F., Ravel, D., Mottier, D. and Rault, G., 2016. Modulating innate and adaptative immunity by (R)-roscovitine: potential therapeutic opportunity in cystic fibrosis J. Innate Immunity 8, 330-349.
  3. Riazanski, V., Gabdulkhakova, A.G., Boynton, L.S., Eguchi, R.R., Deriy, L.V., Hogarth, D.K., Loaëc, N., Oumata, N., Galons, H., Brown, M.E., Shevchenko, P., Gallan, A.J., Yoo, S.G., Naren, A.P., Villereal, M.L., Beacham, D.W., Bindokas, V.P., Birnbaumer, L., Meijer, L. and Nelson, D.J., 2015. TRPC6 channel translocation into phagosomal membrane augments phagosomal function. Proc. Natl. Acad. Sci. USA 112, E6486-6495.
  4. A Phase II, dose ranging, multicenter, double-blind, placebo controlled study to evaluate safety and effects of (R)-roscovitine in subjects with Cystic Fibrosis, homozygous for the F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa, a study involving 36 CF patients (24 treated, 12 controls). ANSM authorization Sept. 15, 2015.
  5. Norez, C., Vandebrouck, C., Bertrand, J., Noel, S., Durieu, E., Oumata, N., Galons, H., Antigny, F., Chatelier, A., Bois, P., Meijer, L. and Becq, F., 2014. Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. Br. J. Pharmacol. 171, 4831-4849.

Polycystic Kidney Disease (PKD)

  1. Billot, K., Coquil, C., Villiers, B., Josselin-Foll, B., Desban, N., Delehouzé, C., Oumata, N., Le Meur, Y., Boletta, A., Weimbs, T., Grosch, M., Witzgall, R., Saunier, S., Fischer, E., Pontoglio, M., Fautrel, A., Mrug, M., Wallace, D., Tran, P.V., Trudel, M., Bukanov, N., Ibraghimov-Beskrovnaya, O. and Meijer, L., 2018. Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for R-roscovitine and s-CR8. Am. J. Physiol. – Renal Physiol. 315, F57 – F73.
  2. Husson, H., Moreno, S., Smith, L.A., Smith, M.M., Russo, R.J., Carlson, G., Pitstick, R., Sergeev, M., Ledbetter, S.R., Bukanov, N.O., Shah, J., Billot, K., Meijer, L., Beier, D.R. and Ibraghimov-Beskrovnaya, O., 2016. Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis. Human Mol. Genet. 25, 2245-2255.
  3. Bukanov, N.O., Moreno, S.E., Natoli, T.A., Rogers, K.A., Smith, L.A., Ledbetter, S.R., Oumata, N., Galons, Meijer, L. and Oxana Ibraghimov-Beskrovnaya, O., 2012. CDK inhibitors R-roscovitine and S-CR8 effectively inhibit renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle 11, 4040-4046.
  4. Bukanov, N.O., Smith, L.A., Klinger, K.W., Ledbetter, S.R. and Ibraghimov-Beskrovnaya, O., 2006. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444, 949-952.

Alzheimer’s Disease (AD) & Down Syndrome (DS)

  1. Nguyen, T. L., Duchon, A., Manousopoulou, A., Loaëc, N., Villiers, B., Pani, G., Karatas, M., Mechling, A.E., Harsan, L.A., Limanton, E., Bazureau, J.P., Carreaux, F., Garbis, S.D., Meijer, L. and Hérault, Y., 2018. Correction of cognitive deficits in mouse models of Down syndrome by pharmacological inhibitor of DYRK1A. Dis. Model Mech. 11, dmm035634
  2. Cam*, M., Durieu*, E., Bodin, M., Manousopoulou, A., Koslowksi, S., Vasylieva, N., Barnych, B., Hammock, B., McMahen, R.L., Strynar, M.J., Bohl, B., Koch, P., Omori, C., Yamamoto, K., Hata, S., Suzuki, T., Karg, F., Gizzi, P., Erakovic-Haber, V., Portelius, E., Pannee, J., Blennow, K., Zetterberg, H., Garbis, S., Auvray, P., Gerber, H., Fraering J., Fraering P.C. and Meijer, L., 2018. Induction of amyloid-β42 production by fipronil and other pyrazole insecticides. J. Alzheimer’s Disease 62, 1663-1681.
  3. Loaëc, N., Attanasio, E., Villiers, B., Durieu, E., Tahtouh, T., Cam, M., Davis, R.A., Alencar, A., Roué, M., Bourguet-Kondracki, M.L., Proksch, P., Limanton, E., Guiheneuf, S., Carreaux, F., Bazureau, J.P., Klautau, M. and Meijer, L., 2017. Marine derived 2-aminoimidazolone alkaloids. Leucettamine B -related polyandrocarpamines inhibit mammalian and protozoan DYRK &/CLK kinases. Marine Drugs 15, 316.
  4. Nguyen, T.L., Fruit, C., Hérault, Y., Meijer, L. and Besson, T., 2017. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature. Expert Opin. Ther. Pat. 27, 1183-1199.
  5. Fant, X., Durieu, E., Chicanne, G., Payrastre, B., Sbrissa, D., Shisheva, A., Limanton, E., Carreaux, F., Bazureau, J.P. and Meijer, L., 2014. Cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases Leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer’s disease. Mol. Pharmacol. 85, 441-450. 
  6. Hochard, A., Oumata, N., Durieu, E., Bettayeb, K., Gloulou, O., Fant, X., Buron, N., Porceddu, M., Borgne, A., Galons, H., Flajolet, M. and Meijer, L., 2013. Aftins increase amyloid-β42, lower amyloid-β38 and do not alter amyloid-β40 in vitro production: towards a chemical model of Alzheimer’s disease? J. Alzheimer’s Disease 35, 107-120.
  7. Tahtouh, T., Elkins, J.M., Filippakopoulos, P., Soundararajan, M., Burgy, G., Durieu, E., Cochet, C., Schmid, R.S., Lo, D.C., Delhommel, F., Oberholzer, A.E., Pearl, L.H., Carreaux, F., Bazureau, J.P., Knapp, S. and Meijer, L., 2012. Selectivity, cocrystal structures and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J. Med. Chem. 55, 9312-9330.
  8. Debdab, M., Carreaux, F., Renault, S., Soundararajan, M., Fedorov, O., Filippakopoulos, P., Lozach, O., Babault, L., Tahtouh, T., Baratte, B., Ogawa, Y., Hagiwara, M., Eisenreich, A., Rauch, U., Knapp, S., Meijer, L. and Bazureau, J.P., 2011. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B. Modulation of alternative pre-RNA splicing. J. Med. Chem. 54, 4172-4186.
  9. Portelius, E., Durieu, E., Bodin, M., Cam, M., Pannee, J., Leuxe, C., Mabondzo, A., Oumata, N., Galons, H., Lee, J., Chang, Y.T., Stüber, K., Koch, P., Fontaine, G., Potier, M.C., Manousopoulou, A., Garbis, S., Covaci, A., Van Dam, D., De Deyn, P., Karg, F., Flajolet, M., Omori, C., Hata, S, Suzuki, T., Blennow, K., Zetterberg, H. and Meijer, L., 2016. Specific triazine herbicides induce amyloid β 42 production. J. Alzheimer’s Disease 54, 1593-1605.


  1. Marlier, Q., Jibassia, F., Verteneuil, S., Linden, J., Kaldis, P., Meijer, L., Nguyen, L., Vandenbosch, R. and Malgrange, B., 2018. Genetic and pharmacological inhibition of Cdk1 provides neuroprotection towards ischemic neuronal death. Cell Death Discov. 4, 43.

DYRK Conference

March 28 – April 1st 2017 | Saint Malo, France

Download PDF (1,4MB)